In Anaheim, California, the U.S. Food and Drug Administration (FDA) is taking significant steps to further integrate itself into the rapidly evolving landscape of medical technologies based on artificial intelligence and machine learning. The FDA recently announced its intention to establish a new advisory committee in the upcoming year, with a particular focus on digital health. This committee's mandate will encompass not only AI but also therapeutic apps, software, wearable devices, remote patient monitoring programs, and virtual and augmented reality tools.
During a town hall event at the AdvaMed MedTech Conference, Troy Tazbaz, the Director of the FDA's Digital Health Center of Excellence, shared insights into the agency's forward-looking approach. He expressed the agency's strong desire to collaborate more closely with the industry to address significant healthcare needs.
Tazbaz emphasised the need for a more aligned and interactive relationship between the FDA and stakeholders in the digital health space. He believes that simply transactional engagements will not suffice and that there is a growing need for ongoing dialogue.
This move by the FDA demonstrates its recognition of the pivotal role that digital health technologies, AI, and related innovations play in modern healthcare. By creating this advisory committee, the FDA is seeking to provide a platform for continuous engagement and collaboration, where industry experts and regulatory bodies can work together to ensure the safety, efficacy, and accessibility of these groundbreaking technologies for the benefit of healthcare and patients alike.
Click here to read the original news story.